Building the Future of Health Sciences

OrbiMed seeks to invest globally in world-class healthcare companies to help drive innovation, address unmet medical needs, and improve patient outcomes.

Providing tailored financing solutions and global team resources to help build
world-class healthcare companies.

From biopharmaceuticals to medical devices, digital health, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer, and more productive lives.

We have been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 130 distinguished scientific, medical, investment, and other professionals manages approximately $17 billion across public and private company investments worldwide.

How We Invest
patient smiling

Meet Our Companies Driving Healthcare Innovation

Messenger RNA targeting to create life-saving therapeutics

ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies.

Learn More

People with cancer can’t wait. Let’s go.

SpringWorks applies a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer.

Learn More

Pushing targeted oncology drug discovery to new heights

Treeline Biosciences is pursuing molecular targets in oncology that are validated but difficult to drug, leveraging its four pillars of drug discovery: mechanistic biology, medicinal chemistry, computational science, and structural biology and protein science.

Learn More

Missing Link in Telehealth

TytoCare is transforming primary care by putting health in the hands of consumers.

Learn More

$17B

AUM

500+

Portfolio
Companies

130+

Total
Professionals

12

Global
Locations

130+

Venture-backed
IPOs

Amolyt Pharma Logo

Portfolio News

Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

Read More link
Adicet Bio Logo

Portfolio News

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and...

Read More link
Alpine Immune Sciences Logo

Portfolio News

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Read More link

Portfolio News

Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

Read More link

Portfolio News

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and...

Read More link

Portfolio News

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Read More link
img img img img img img img img img